What is Atripla (efavirenz, emtricitabine, tenofovir)?
Atripla (efavirenz, emtricitabine, tenofovir), a fixed dose combination of three widely used antiretroviral drugs, to be taken as one tablet once a day, is indicated for use alone as a complete treatment option or in combination with other antiretroviral agents for the treatment of human immunodeficiency virus -1 (HIV-1) infection in adult patients. 2. Why is the approval of Atripla (efavirenz, emtricitabine, tenofovir) important? The approval of Atripla is significant because it markedly simplifies the drug regimen for HIV-1 infected adults. This product offers a one pill, once a day treatment option for patients receiving antiretroviral therapy. There has been interest in simplifying treatment options which may potentially improve the patients ability to adhere to the treatment and result in long-term effective control of HIV-1. 3. What is meant by a fixed-dose combination? A fixed-dose combination package has two or three drugs in a single pill. Whereas a co-packaged product refers
